High-throughput phenotypic screening of the human spermatozoon

Zoe C Johnston^{1,2}, Franz S Gruber^{1,2}, Sean G Brown³, Neil R Norcross⁴, Jason Swedlow², Ian H Gilbert⁴ and Christopher L R Barratt¹

¹Division of Systems Medicine, School of Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK, ²National Phenotypic Screening Centre, School of Life Sciences, University of Dundee, Dundee, UK, ³School of Applied Sciences, Abertay University, Dundee, UK and ⁴Drug Discovery Unit, Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, Dundee, UK

Correspondence should be addressed to C L R Barratt; Email: c.barratt@dundee.ac.uk

Abstract

Despite recent advances in male reproductive health research, there remain many elements of male infertility where our understanding is incomplete. Consequently, diagnostic tools and treatments for men with sperm dysfunction, other than medically assisted reproduction, are limited. On the other hand, the gaps in our knowledge of the mechanisms which underpin sperm function have hampered the development of male non-hormonal contraceptives. The study of mature spermatozoa is inherently difficult. They are a unique and highly specialised cell type which does not actively transcribe or translate proteins and cannot be cultured for long periods of time or matured *in vitro*. One large-scale approach to both increasing the understanding of sperm function and the discovery and development of compounds that can modulate sperm function is to directly observe responses to compounds with phenotypic screening techniques. These target agnostic approaches can be developed into high-throughput screening platforms with the potential to drastically increase advances in the field. Here, we discuss the rationale and development of high-throughput phenotypic screening platforms for mature human spermatozoa and the multiple potential applications these present, as well as the current limitations and leaps in our understanding and the capabilities needed to overcome them. Further development and use of these technologies could lead to the identification of compounds which positively or negatively affect sperm cell motility or function or novel platforms for toxicology or environmental chemical testing among other applications. Ultimately, each of these potential applications is also likely to increase the understanding within the field of sperm biology.

Reproduction (2022) **163** R1–R9

Introduction

Recently, there have been several significant developments in male reproductive health that have not only increased our understanding of basic mechanisms but also opened exciting areas of research. One is uncovering how epigenetic modification of the paternal gamete can potentially have profound effects on the health of subsequent generations (Bodden *et al.* 2020, Lismer *et al.* 2021). Another is understanding how male reproductive health is increasingly viewed as a sentinel marker for somatic health issues (Choy & Eisenberg 2018, Del Giudice *et al.* 2021) and the health of subsequent offspring (Kasman *et al.* 2020). However, there are two key areas where progress remains limited, namely (i) the diagnosis of and non-medically assisted reproduction (MAR) treatment of men with sperm dysfunction; (ii) development of new male contraceptives.

This review outlines these two areas including discussing the driving requirement for progress. A common roadblock limiting the development, namely the

relatively rudimentary understanding of the underlying physiology and function of the mature spermatozoon, is presented. The focus is discussing the potential uses of a high-throughput phenotypic screening assay of the mature human spermatozoon. This can be used as a platform technology to devise new diagnostic tools and non-MAR therapies, as a tool for the development of new targets and drugs for male contraception, and to improve our underlying knowledge of the cell.

Background

Sperm dysfunction, diagnosis, and non-MAR treatment

A plethora of studies demonstrate that our understanding of the physiology of the mature human spermatozoon is quite limited and that this is a significant roadblock to the development of badly needed diagnostic and therapeutic tools (Barratt *et al.* 2017, 2021, De Jonge & Barratt 2019, Schlegel *et al.* 2021). Consider for example the development and use of sperm function assays.

There is clear information that classical sperm function tests such as the generation of reactive oxygen species (ROS) and assessment of subsequent damage to the cell have significant clinical value (see reviews [Oehninger & Ombelet 2019](#), [Aitken & Bakos 2021](#)). However, these assays are yet to be translated into robust tests that are routinely used in the clinical setting. Why? There are several reasons, but primary among these is our relatively low knowledgebase of the mature spermatozoon and what separates function from dysfunction at a phenotypic level within these assays. One example illustrates this – the complexities of ROS generation and the assessment/impact of ROS damage. Thirty years ago, seminal work from [Aitken et al. \(1991\)](#) provided clear evidence that generation of ROS in a semen sample had a negative impact on the chances of achieving an *in vivo* pregnancy in 139 sub-fertile couples. A plethora of subsequent experiments unveiled the complexity of ROS generation as a ‘friend and foe’ to the spermatozoon and the challenges of assessing subsequent damage to the cell. Consequently, developing an assay(s) that could easily reflect pathological ROS generation and damage with clear cut-off values and reference ranges is not simple. Suffice it to say, we still do not have sufficient detailed biological knowledge to illuminate clear diagnostic assays. John Aitken succinctly summarised the reality of the situation as there is a ‘rampant uncertainty’ about which assays to use ([Aitken 2021](#)).

A detailed understanding of the physiology of a sperm cell is not only important for the development of diagnostic tools but also to develop rational non-MAR treatment. For example, to successfully use antioxidants for the treatment of sperm dysfunction, its first necessary to demonstrate that oxidative stress is the cause of infertility. The continual unsuccessful use of antioxidants for male infertility is a testament to the fact that we are yet to solve this conundrum ([Aitken 2021](#)).

Male contraception

Remarkably, there remain only two well-established methods of male contraception, namely vasectomy and condoms both of which have inherent disadvantages limiting global utilisation. Progress in male hormonal contraception has been slow particularly considering that promising trials were published 25 years ago ([World Health Organization Task Force on Methods for the Regulation of Male Fertility 1996](#)) and currently, despite much discussion, there are no products on the horizon ([Reynolds-Wright & Anderson 2019](#), [Thirumalai & Amory 2021](#)). Moreover, while there has been significant activity to elucidate potential key targets for non-hormonal contraception, high-quality human targets are yet to be realised ([Long et al. 2021](#)). Although there are possibilities for targets allowing interruption of spermatogenesis and/or manipulation of the epididymal

environment, of particular concern, is the scarcity of new targets in the mature human spermatozoon.

As indicated, a fundamental challenge in andrology remains the paucity of knowledge of the physiological workings of the normal (and dysfunctional) spermatozoon. Although progress has been made, for example using proteomics or electrophysiology, our discipline still lacks real intensity in these areas. For example, we do not have a detailed understanding of the quantitative protein composition of the spermatozoa, including post-translational modifications and protein interactions (cf sea urchins ([Trötschel et al. 2020](#))). Electrophysiological data are still limited on patient samples ([Brown et al. 2019](#)) and single-cell analysis and imaging are only recently gaining traction ([Moscatelli et al. 2017](#), [Kandel et al. 2020](#), [Nandagiri et al. 2021](#)). The power of technology is impressive but uptake and overall development in the discipline of human sperm biology have been relatively slow.

High-throughput phenotypic screening

High-throughput phenotypic screening in general biology

Phenotypic screening is a target agnostic approach where phenotypic responses to compounds are directly observed. Therefore, compounds that produce a desired phenotype can be identified even when knowledge of molecular targets are limited. Further, screening can be carried out to probe different phenotypes that may have different physiological relevance. However, care must be taken that the phenotypic assay is relevant to the disease context in the patient ([De Rycker et al. 2018](#)). To achieve this, usually, it is necessary to develop screening cascades with a variety of secondary assays ([Field et al. 2017](#)).

Compounds that produce phenotypic responses or ‘hit’ compounds can be used to identify novel targets, and/or can be modified to modulate the phenotype further. Phenotypic screening is a common approach in drug discovery ([Gilbert 2013](#), [Moffat et al. 2017](#)) and has been successfully used to discover several new compounds for major disorders and diseases, for example, fragile X syndrome ([Kaufmann et al. 2015](#)), hepatitis C ([Gao et al. 2010](#)), cryptosporidiosis ([Love et al. 2017](#), [Jumani et al. 2019](#), [Love & McNamara 2021](#)), and malaria ([Baragaña et al. 2015](#), [Baragaña et al. 2016](#), [Antonova-Koch et al. 2018](#)).

In addition to identifying potential drug candidates, phenotypic screening can provide insights to improve the understanding of biology of the cells or complex model systems in normal or diseased states by identifying novel, chemical tools ([Moffat et al. 2017](#)). Phenotypic compound profiles can be created through the generation and analysis of complex and rich datasets that describe a multitude of cellular parameters (e.g. morphology, gene/protein expression levels) or functions (e.g. velocity). These profiles can provide

a rationale for the identification of molecular targets (target deconvolution) to determine the mechanism of action of hit compounds (Chandrasekaran *et al.* 2021, Hughes *et al.* 2021, Ziegler *et al.* 2021). While the target deconvolution of hits can be challenging, this provides valuable information in understanding the fundamental biology of the cell for medicinal chemistry optimisation of drug hits and leads and the potential clinical use of a compound.

As a platform for drug discovery and for further molecular understanding, the inherent advantages of the phenotypic screening approach are readily translatable to the human spermatozoon. Several functional and clinically relevant *in vitro* assays, such as sperm motility, acrosome reaction, and intracellular calcium flux assays, have the potential to form a basis for phenotypic screening assays.

Development of phenotypic screening for human spermatozoa

Development of a high-throughput phenotypic assay for the assessment of human sperm function brings significant technical obstacles. For example, the system must be largely automatic (require minimal labour input), requiring sophisticated robotics, and directly assess the effects of numerous (thousands) compounds on sperm cell function within a short time. It must also be based on robust (good Z' score) and reproducible assays, with a good signal-to-noise ratio and a measurable end-point. We have addressed these challenges and developed a high-throughput phenotypic platform (Fig. 1) to measure the motility (Gruber *et al.* 2020), as well as other key attributes, of the human spermatozoon

(Fig. 2). The platform utilises a fully automated robotics platform to carry out primary screening assays in a plate-based format and resulting data analysis can be largely automated to process the large amounts of data these high-throughput screens produce. The flexibility and automation allow for multiple aspects of sperm function to be interrogated with different assays (Fig. 2). This platform has been utilised to screen several libraries to demonstrate that the assay is scalable, provides consistent biological data compared to traditional sperm function assays such as computer-aided sperm analysis (CASA), and rapidly samples sufficient numbers of cells. In addition, the platform also provides the opportunity for further developments, that is to adapt the screening platform to other assays and purposes. For example, the addition of conditions that support capacitation, the flexibility of compound addition and incubation times (Fig. 1), or the opportunity to adapt the technology to answer different questions with different physiologically relevant environments.

Now that a high-throughput phenotypic assay is available, what opportunities arise? We identify five areas to illustrate the potential power of this technology. Although these are presented as separate entities, they are not exhaustive or mutually exclusive and there is a significant overlap such that data from one area inform another.

Identification of compounds negatively affecting human sperm function for male contraception

A premise for a phenotypic screen is to have an assay that has physiological/disease relevance. Sperm motility is ideally suited as it is easy to measure and is related

Figure 1 The flexibility of the high-throughput phenotypic screening platform and automation. The high-throughput sperm screening platform developed by Gruber *et al.* utilises a 384-well plate format and automation through liquid-handling machines and interchangeable measurement devices. Sperm cells from donor or patients can be observed within the system, and although the focus of platform development has been human sperm, the platform can also be used for the examination of animal sperm such as bovine. Depending on the assay format, non-capacitating or capacitating conditions can be used, and cells can be exposed to library compounds for defined periods of time, as well as controls and stains appropriate for each application. Interchangeable automated protocols and functional read-out devices can be used within the platform to allow assay flexibility. For each high-throughput application, complex automated, or semi-automated, data analysis is required to identify compounds with either positive or negative phenotypic effect. Identification of hit compounds is followed by further dose-response confirmation.

Figure 2 Interchangeable assay modules can be used with the high-throughput platform. The phenotypic screening platform is designed to work with interchangeable read-out modules to allow multiple assays to be carried out on the same platform. The primary output of the platform discussed in this review is the sperm motility assay module (A) that consists of a microscopy-based read-out followed by automated sperm tracking and analysis. This provides data on sperm numbers, motility, kinematics, hyperactivation, and swimming patterns at multiple time points. Further examples of other read-out modules and assays that can be achieved with the high-throughput screening platform are illustrated, including a quantitative acrosome reaction, sperm cell viability assays using flow cytometry (B), and intracellular calcium quantification using a spectrofluorometer (C). Furthermore, these read-out modules can be multiplexed together to gather additional information within the same automated cycle. For example, this could be a flow cytometry-based assay examining the acrosome reaction or cell viability in response to compounds that follow on from a motility read-out of the same cell population.

to both *in vivo* and *in vitro* fertility (Tomlinson *et al.* 1999). Consequently, a phenotypic assay based on sperm motility is a logical approach for the assessment for contraceptive purposes. This is our primary strategy for the identification of compounds that adversely affect sperm motility, as part of the Bill and Melinda Gates Foundation Contraceptive Program. <https://gcgh.org/andchallenges.org/challenge/accelerating-discovery-non-hormonal-contraceptives>.

Several different strategies can be adopted to achieve this goal. For example, the assessment of libraries enriched or specifically containing repurposing compounds such as the ReFRAME library (<https://reframedb.org/>; Janes *et al.* 2018). A primary advantage of this approach is that if a compound(s) of interest is identified then it is likely to be accompanied by significant safety/clinical development data thus facilitating more rapid development and potential translational impact. Screening of repurposing libraries is a successful approach as exemplified by its use in anti-cryptosporidial (Janes *et al.* 2018) and anti-leishmanial drug development (Patterson & Fairlamb 2019) that have led to rapid progression of compounds into clinical trials, clofazimine for cryptosporidiosis and fexinidazole for visceral leishmaniasis.

A complementary strategy could include using chemogenomic libraries. These are known small molecule pharmacological agents against a broad

spectrum of annotated targets/pathways. Thus, the emphasis when using these is not on generation of chemical matter as for a medicinal chemistry programme but for generating information on potential targets and informing follow-up on target identification (Jones & Bunnage 2017). Examples of such libraries include Sigma library of pharmacologically active compounds (LOPAC1280; www.sigmaaldrich.com), Prestwick Chemical library (www.prestwickchemical.com), both of which have been used in a large number of publications.

Another approach could be the use of pharmacologically focused libraries that contain known inhibitors or chemical scaffolds for target classes such as protein kinases (Brenk *et al.* 2008, Woodland *et al.* 2015). Kinases play a significant role in human sperm function and testing these libraries could be helpful in addressing their role. As it's a phenotypic screen and the whole intact spermatozoon is being assessed, a key advantage of such annotated libraries is that not only one or several kinases are examined but the whole kinome is examined, leading to an understanding of kinases in their biologically relevant states.

Following initial screening and hit identification, hits must be confirmed, usually through the re-supply of fresh chemical compound, re-testing, and subsequent testing in a variety of biological and pharmacological assays, as guided by a target candidate profile. The aim of this work is to optimise the compounds to increase potency and improve physicochemical, pharmacokinetic, and safety profiles. In case of sperm, an initial important assay is to check the compounds in a mammalian cell line (counter screen) to ensure that there is a measurable selectivity window between sperm motility inhibition and general cytotoxicity. Further assays include *in vitro* physicochemical profiling such as solubility and metabolic stability in liver microsomes. This screening cascade would also include a series of additional assays, both cellular and animal models, to assess the biological activity of key compounds against spermatozoa and their likely effectiveness as a contraceptive.

Although the use of phenotypic screening of human sperm is still in the early stages, it potentially represents a disruptive technology in the arena. Several interesting preliminary compounds have been identified using the above approaches (Gruber *et al.* 2020) and are currently generating potential start points for a contraceptive medicinal chemistry programme. Disulfiram is one example of an identified compound that significantly reduces motility (70% reduction at 10 μ M) within a relatively short-time frame (1 h). Although not developable as a male contraceptive, due to likely side-effects, the identification of disulfiram indicates that compounds with robust contraceptive activity can be identified using this approach for either progression into a medicinal chemistry programme or for use as a tool compound for target identification or as a control compound for further assay development.

Identification of compounds positively affecting sperm motility potential for non-MAR therapy

Identifying compounds that increase sperm motility (but do not adversely affect other critical aspects of sperm function) has been a key goal in clinical andrology for decades. If effective and safe, such compounds could be used in MAR treatments such as intrauterine insemination (Martins da Silva *et al.* 2017, Tardif *et al.* 2014), where the objective would be to temporarily improve the motility of the cell so that there were a higher number of functional cells able to reach the site of fertilisation and/or interact with the egg. The compounds could be added to the sperm cells during the normal routine processing of the sample for insemination and if effective would make treatment more cost effective, less complex, and widely available as treatment became available for more patients.

While the screening system for examining compounds that increase motility is effectively the opposite to contraception, it's not simply a case of observing a different read-out – increase vs decreases in motility. The systems need to be set up differently as the aims are diametrically opposed. For contraception purposes, a fast-irreversible block of motility is the goal. For enhancement of fertility, motility would need to be relatively long lasting rather than a temporary boost, and conversely, it's important not to overstimulate the cell to avoid metabolic exhaustion. As such the assessment time periods are considerable. Also, it is necessary to study the effects in different environments, for example, non-capacitating, capacitating conditions, to examine if the effect is modified or even negated as the cell is processed and moves towards the egg (Tardif *et al.* 2014). Different counter screening is also necessary for example to eliminate undesired adverse outcomes on the fertilising ability of the cells such as avoiding premature stimulation of the acrosome reaction (AR). Using the phenotypic motility screening approach, in preliminary data, several compound classes have been identified which warrant such further investigation (Gruber *et al.* 2021 in press).

In this case, a similar library selection strategy to identify compounds, which have a negative effect on sperm function, as in the contraceptive approach, was adopted, for example, chemogenomic and focused libraries. However, it would be interesting to examine the repurposing of target-annotated libraries as identification of compounds in this area may facilitate a more rapid translation to the clinic, where safety data for the compound already exists or the compound is already in therapeutic use for another indication.

Improving our understanding of the functional mature spermatozoon

There are several areas where a phenotypic assay could potentially be utilised to improve our fundamental knowledge of the cell. For example, understanding

the role of ion channels. A wealth of data suggests that these are critical for human sperm function but even the basic operation of the most widely studied channel – CatSper – remains somewhat a mystery (Brown *et al.* 2019). Furthermore, we don't have a full inventory of the functional ion channel repertoire of the human sperm plasma membrane.

One approach to examine ion channel function in the human spermatozoon would be to screen against large commercially available libraries containing putative or known ion channel inhibitors. Initial experiments could assess the effects on, for example, basal motility and kinematics. This would address the question of what role ion channels play in the maintenance of sperm motility. Further experiments could extend in assessing the cells incubated under capacitating and non-capacitating conditions providing important insight into the role of capacitation. Moreover, as assessment of hyperactivation is standard in CASA (Mortimer & Mortimer 2013), it is easily translatable to phenotypic screening. The importance of ion channels in maintenance and induction of hyperactivation could then be examined on a high-throughput scale including assessment of the dynamic nature of these events.

An important issue in the advancement of andrology is the lack of consistency between research groups, and indeed clinics, in sperm handling techniques and in culture media composition. This may, in part, explain some of the uncertainty and conflicting literature in the field (Hernández-Silva *et al.* 2020). For example, recent work elucidating the mechanistic role of albumin in activating the proton channel hHv1 and capacitation of human sperm (Zhao *et al.* 2021) highlights the importance of sufficient levels of albumin in sperm culture media to fully support capacitation. Experiments carried out in media with differing levels of albumin have the potential to yield differing results due to impaired capacitation. A plate-based screening platform may also provide an approach for examining the phenotypic effects of different culture conditions and media additives on the mature human sperm cell in parallel. The scale and flexibility of high-throughput platforms could also aid in addressing other conflicting data within the field, where there is a particular need to screen large numbers of compounds/samples under consistent conditions, for example the action of endogenous steroids and plant triterpenoids on the regulation of human CatSper (Mannowetz *et al.* 2017, Brenker *et al.* 2018, Rehfeld 2020).

Understanding is not limited to investigation of the normal spermatozoon. While we have not examined it, the system could be used to test well-defined cohorts of patient samples. For example, when determining effects of compounds to potentially increase motility, do all patients with isolated asthenozoospermia have the same kinetic responses? Moreover, these patients' sample could be assessed under the same conditions

(e.g. capacitation timing) determining the dynamics of individual responses.

Large scale screening of potential toxicants environmental/occupational chemicals

There is a growing body of data on the potential direct effect of environmental chemicals. Although currently this work is largely restricted to examination of outputs such as calcium (Schiffer *et al.* 2014, Rehfeld *et al.* 2020, Birch *et al.* 2021), several small scale studies have indicated direct effects of specific environmental chemicals and mixtures on sperm motility (Grizard *et al.* 2007, Pant *et al.* 2013, Sumner *et al.* 2019). High-throughput examination of sperm motility (and other functional attributes) could provide complementary data on a larger scale and may be particularly relevant, where assessing the complexities of interactions between compounds, which require quantum leaps in throughput.

Future method development

In addition to the assessment of motility, we have developed a phenotypic screen for the AR that uses lectins well established in sperm physiology (Mortimer *et al.* 1987). Importantly, we have multiplexed the motility and AR phenotypic assays so that, if required, in one well we can report the activity of a compound on two key aspects of sperm function (Gruber *et al.* 2020).

The development of increasing numbers of *in vitro* technologies for cell-based assays further augments the potential benefits of phenotypic screening. In essence, having established a fundamental platform, if a robust and functionally appropriate assay is available, it could be miniaturised and adapted for use in the phenotypic screen. In sperm biology, this could range from examination of tyrosine phosphorylation (Matamoros-Volante *et al.* 2018) to assessment of membrane potential with the latter recently associated with fertilising capacity (Brown *et al.* 2016, Baro Graf *et al.* 2019, Molina *et al.* 2019).

A physiologically- and clinically relevant phenotypic assay is a cornerstone of phenotypic screening. While *in vitro* assessment of sperm motility is used clinically and has both diagnostic and predictive value (Tomlinson *et al.* 1999), it is assessed in non-viscous media. In contrast, spermatozoa spend their functional life in more viscoelastic environments in the female tract, hence adapting and developing *in vitro* tests to make them more physiologic may be helpful. For example, adaption of the viscous media penetration assay (Kremer test) that is used as a simple, reliable but very low-throughput method to demonstrate the effect of compounds on sperm motility would be a valid phenotype (Williams *et al.* 2015, McBrinn *et al.* 2019, Yuan *et al.* 2020).

While the focus of this review is on the human spermatozoon, the same technology can also be adapted and fine-tuned for use on animal spermatozoa.

For example, we have modified the high-throughput phenotypic motility screening assay so it can be used on conventional and sex-sorted cryopreserved bovine spermatozoa (McBrinn unpublished) opening the technology to research in animal reproduction.

Limitations of phenotypic screening

High-throughput phenotypic screening of the human spermatozoon requires expensive technology that is not routinely available within academic settings. Moreover, any phenotypic assay is by necessity a compromise between the need to rapidly obtain information on large numbers of compounds and having an assay that represents the functions of the cell. For example, media conditions can either be non-capacitating or support capacitation, and cells must be prepared and washed for dispensing rather than examining compound exposure in the presence of seminal plasma. Therefore secondary, lower-throughput assays are required to fully examine the effects of hit compounds.

Moreover, while compound identification and effect are the remit of phenotypic screening, it's only a platform for further study. Identification of the target (target deconvolution) and detailed mechanisms of action (MOA) studies are usually required, and in some cases, these can be difficult to achieve. For example, McBrinn *et al.* (2019) and colleagues describe the hurdles in examining the MOA of a well-known phosphodiesterase inhibitor of sperm function – Trequinsin. In some areas, despite numerous years of research, the MOA of compounds can be poorly understood even when these are drugs commonly used to treat disease.

Fortunately, along with the complex screening technologies and physicochemical assessments available with high-throughput screening technologies and drug discovery, within andrology further functional assays are available to be adapted for both hit confirmation and target deconvolution. For example, adapted viscous media penetration assays can be used to examine the effects on prepared cells or raw semen and sperm cells subsequent ability to penetrate a physiologically relevant viscoelastic medium (Tardif *et al.* 2014, McBrinn *et al.* 2019).

For further method development, some biological challenges remain that limit the adaptations of phenotypic screening of the human spermatozoon. For AR, while we can assess the effects of compounds on their potential to induce AR, for contraceptive purposes, it would be interesting to see if compounds were able to block physiological induction of AR. However, to achieve this we would need to have a single, robust and reliable physiological agonist, which is unfortunately not yet available.

As high-throughput systems aim to automate as much of the workflow as possible, the technology has largely been utilised with adherent cell lines. These, for the

most part, can be cultured over several days or even weeks, proliferate, and are well characterised. Some of the major challenges of adapting these technologies to andrology come from the nature of human sperm cells. Sperm cells are highly specialised non-dividing cells, unique in shape and size with specialised organelles that do not actively transcribe or translate proteins. In practical terms, the supply of cells is limited by donor or patient numbers and availability, and cells cannot be cultured for long periods of time. Their preparation from raw semen is also limited to a time-consuming process that at least so far cannot be automated. Therefore, in all the assays described above, the sperm cells themselves are often the limiting factor and this must be considered while planning their use in phenotypic screening or with high-throughput technologies.

Conclusions

In conclusion, we have discussed the potential advantages of using a newly available phenotypic screening platform for the human spermatozoa. Work is in its infancy, but it has the potential to facilitate the discovery of new areas of sperm biology to improve our understanding of this highly specialised cell type. Platform technologies such as this will help to address key log jams in the development of compounds to treat and conversely impair fertility (contraception), improve diagnostics assays, and understanding. It will be exciting to see what new avenues this type of investigation could bring to sperm biology.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation (INV-007117). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

Author contribution statement

C L R B designed the concept and framework of the paper and wrote the first draft. All authors contributed to subsequent drafts and to the final editing of the manuscript. All authors approved the submission of the final manuscript.

Acknowledgements

The authors thank Dr Steve Publicover for critical reading of the manuscript.

References

- Aitken RJ 2021 Antioxidant trials – the need to test for stress. *Human Reproduction Open* **2021** hoab007. (<https://doi.org/10.1093/hropen/hoab007>)
- Aitken RJ & Bakos HW 2021 Should we be measuring DNA damage in human spermatozoa? New light on an old question. *Human Reproduction* **36** 1175–1185. (<https://doi.org/10.1093/humrep/deab004>)
- Aitken RJ, Irvine DS & Wu FC 1991 Prospective analysis of sperm-oocyte fusion and reactive oxygen species generation as criteria for the diagnosis of infertility. *American Journal of Obstetrics and Gynecology* **164** 542–551. ([https://doi.org/10.1016/s0002-9378\(11\)80017-7](https://doi.org/10.1016/s0002-9378(11)80017-7))
- Antonova-Koch Y, Meister S, Abraham M, Luth MR, Ottillie S, Lukens AK, Sakata-Kato T, Vanaerschot M, Owen E, Jado JC *et al.* 2018 Open-source discovery of chemical leads for next-generation chemoprotective antimalarials. *Science* **362** eaat9446. (<https://doi.org/10.1126/science.aat9446>)
- Baragaña B, Hallyburton I, Lee MCS, Norcross NR, Grimaldi R, Otto TD, Proto WR, Blagborough AM, Meister S, Wirjanata G *et al.* 2015 A novel multiple-stage antimalarial agent that inhibits protein synthesis. *Nature* **522** 315–320. (<https://doi.org/10.1038/nature14451>)
- Baragaña B, Norcross NR, Wilson C, Porzelle A, Hallyburton I, Grimaldi R, Osuna-Cabello M, Norval S, Riley J, Stojanovski L *et al.* 2016 Discovery of a quinoline-4-carboxamide derivative with a novel mechanism of action, multistage antimalarial activity, and potent in vivo efficacy. *Journal of Medicinal Chemistry* **59** 9672–9685. (<https://doi.org/10.1021/acs.jmedchem.6b00723>)
- Baro Graf C, Ritagliati C, Stival C, Balestrini PA, Buffone MG & Kröpf D 2019 Determination of a robust assay for human sperm membrane potential analysis. *Frontiers in Cell and Developmental Biology* **7** 101. (<https://doi.org/10.3389/fcell.2019.00101>)
- Barratt CLR, Björndahl L, De Jonge CJ, Lamb DJ, Osorio Martini F, McLachlan R, Oates RD, van der Poel S, St John B, Sigman M *et al.* 2017 The diagnosis of male infertility: an analysis of the evidence to support the development of global WHO guidance-challenges and future research opportunities. *Human Reproduction Update* **23** 660–680. (<https://doi.org/10.1093/humupd/dmx021>)
- Barratt CLR, De Jonge CJ, Anderson RA, Eisenberg ML, Garrido N, Rautakallio Hokkanen S, Krausz C, Kimmins S, O'Bryan MK, Pacey AA *et al.* 2021 A global approach to addressing the policy, research and social challenges of male reproductive health. *Human Reproduction Open* **2021** hoab009. (<https://doi.org/10.1093/hropen/hoab009>)
- Birch MR, Dissing S, Skakkebaek NE & Rehfeld A 2021 Finasteride interferes with prostaglandin-induced CatSper signalling in human sperm. *Reproduction* **161** 561–572. (<https://doi.org/10.1530/REP-20-0287>)
- Bodden C, Hannan AJ & Reichelt AC 2020 Diet-induced modification of the sperm epigenome programs metabolism and behavior. *Trends in Endocrinology and Metabolism* **31** 131–149. (<https://doi.org/10.1016/j.tem.2019.10.005>)
- Brenk R, Schipani A, James D, Krasowski A, Gilbert IH, Frearson J & Wyatt PG 2008 Lessons learnt from assembling screening libraries for drug discovery for neglected diseases. *ChemMedChem* **3** 435–444. (<https://doi.org/10.1002/cmdc.200700139>)
- Brenker C, Schiffer C, Wagner IV, Tüttelmann F, Röpke A, Rennhack A, Kaupp UB & Strücker T 2018 Action of steroids and plant triterpenoids on CatSper Ca(2+) channels in human sperm. *PNAS* **115** E344–E346. (<https://doi.org/10.1073/pnas.1717929115>)
- Brown SG, Publicover SJ, Mansell SA, Lishko PV, Williams HL, Ramalingam M, Wilson SM, Barratt CL, Sutton KA & Da Silva SM 2016 Depolarization of sperm membrane potential is a common feature of men with subfertility and is associated with low fertilization rate at IVF. *Human Reproduction* **31** 1147–1157. (<https://doi.org/10.1093/humrep/dew056>)
- Brown SG, Publicover SJ, Barratt CLR & Martins da Silva SJ 2019 Human sperm ion channel (dys)function: implications for fertilization. *Human Reproduction Update* **25** 758–776. (<https://doi.org/10.1093/humupd/dmz032>)
- Chandrasekaran SN, Ceulemans H, Boyd JD & Carpenter AE 2021 Image-based profiling for drug discovery: due for a machine-learning upgrade? *Nature Reviews: Drug Discovery* **20** 145–159. (<https://doi.org/10.1038/s41573-020-00117-w>)

- Choy JT & Eisenberg ML 2018 Male infertility as a window to health. *Fertility and Sterility* **110** 810–814. (<https://doi.org/10.1016/j.fertnstert.2018.08.015>)
- De Jonge C & Barratt CLR 2019 The present crisis in male reproductive health: an urgent need for a political, social, and research roadmap. *Andrology* **7** 762–768. (<https://doi.org/10.1111/andr.12673>)
- De Rycker M, Baragaña B, Duce SL & Gilbert IH 2018 Challenges and recent progress in drug discovery for tropical diseases. *Nature* **559** 498–506. (<https://doi.org/10.1038/s41586-018-0327-4>)
- Del Giudice F, Kasman AM, Chen T, De Berardinis E, Busetto GM, Sciarra A, Ferro M, Lucarelli G, Belladelli F, Salonia A *et al.* 2021 The association between mortality and male infertility: systematic review and meta-analysis. *Urology* **154** 148–157. (<https://doi.org/10.1016/j.urology.2021.02.041>)
- Field MC, Horn D, Fairlamb AH, Ferguson MA, Gray DW, Read KD, De Rycker M, Torrie LS, Wyatt PG, Wyllie S *et al.* 2017 Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need. *Nature Reviews: Microbiology* **15** 217–231. (<https://doi.org/10.1038/nrmicro.2016.193>)
- Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR *et al.* 2010 Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* **465** 96–100. (<https://doi.org/10.1038/nature08960>)
- Gilbert IH 2013 Drug discovery for neglected diseases: molecular target-based and phenotypic approaches. *Journal of Medicinal Chemistry* **56** 7719–7726. (<https://doi.org/10.1021/jm400362b>)
- Grizard G, Ouchchane L, Roddier H, Artonne C, Sion B, Vasson MP & Janny L 2007 In vitro alachlor effects on reactive oxygen species generation, motility patterns and apoptosis markers in human spermatozoa. *Reproductive Toxicology* **23** 55–62. (<https://doi.org/10.1016/j.reprotox.2006.08.007>)
- Gruber FS, Johnston ZC, Barratt CLR & Andrews PD 2020 A phenotypic screening platform utilising human spermatozoa identifies compounds with contraceptive activity. *eLife* **9** e51739. (<https://doi.org/10.7554/eLife.51739>)
- Gruber FS, Johnston ZC, Norcross NR, Georgiou I, Wilson C, Read KD, Gilbert IH, Swedlow JR, Martins da Silva S & Barratt CLR 2021 Compounds enhancing human sperm motility identified using a high-throughput phenotypic screening platform. *bioRxiv*. (<https://doi.org/10.1101/2021.09.14.460292>)
- Hernández-Silva G, López-Torres AS, Maldonado-Rosas I, Mata-Martínez E, Larrea F, Torres-Flores V, Treviño CL & Chirinos M 2020 Effects of semen processing on sperm function: differences between swim-up and density gradient centrifugation. *World Journal of Men's Health* **39** 740–749.
- Hughes RE, Elliott RJR, Dawson JC & Carragher NO 2021 High-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need. *Cell Chemical Biology* **28** 338–355. (<https://doi.org/10.1016/j.chembiol.2021.02.015>)
- Janes J, Young ME, Chen E, Rogers NH, Burgstaller-Muehlbacher S, Hughes LD, Love MS, Hull MV, Kuhen KL, Woods AK *et al.* 2018 The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis. *PNAS* **115** 10750–10755. (<https://doi.org/10.1073/pnas.1810137115>)
- Jones LH & Bunnage ME 2017 Applications of chemogenomic library screening in drug discovery. *Nature Reviews: Drug Discovery* **16** 285–296. (<https://doi.org/10.1038/nrd.2016.244>)
- Jumani RS, Hasan MM, Stebbins EE, Donnelly L, Miller P, Klopfer C, Besoff K, Teixeira JE, Love MS, McNamara CW *et al.* 2019 A suite of phenotypic assays to ensure pipeline diversity when prioritizing drug-like Cryptosporidium growth inhibitors. *Nature Communications* **10** 1862. (<https://doi.org/10.1038/s41467-019-09880-w>)
- Kandel ME, Rubessa M, He YR, Schreiber S, Meyers S, Matter Naves L, Sermersheim MK, Sell GS, Szczepczyk MJ, Sobh N *et al.* 2020 Reproductive outcomes predicted by phase imaging with computational specificity of spermatozoon ultrastructure. *PNAS* **117** 18302–18309. (<https://doi.org/10.1073/pnas.2001754117>)
- Kasman AM, Zhang CA, Luke B & Eisenberg ML 2020 Association between infertility and mental health of offspring in the United States: a population based cohort study. *Human Fertility* In Press. (<https://doi.org/10.1080/14647273.2020.1805799>)
- Kaufmann M, Schuffenhauer A, Fruh I, Klein J, Thiemeyer A, Rigo P, Gomez-Mancilla B, Heidinger-Millot V, Bouwmeester T, Schopfer U *et al.* 2015 High-throughput screening using iPSC-derived neuronal progenitors to identify compounds counteracting epigenetic gene silencing in fragile X syndrome. *Journal of Biomolecular Screening* **20** 1101–1111. (<https://doi.org/10.1177/1087057115588287>)
- Lismer A, Dumeaux V, Lafleur C, Lambrot R, Brind'Amour J, Lorincz MC & Kimmins S 2021 Histone H3 lysine 4 trimethylation in sperm is transmitted to the embryo and associated with diet-induced phenotypes in the offspring. *Developmental Cell* **56** 671.e6–686.e6. (<https://doi.org/10.1016/j.devcel.2021.01.014>)
- Long JE, Lee MS & Blithe DL 2021 Update on novel hormonal and nonhormonal male contraceptive development. *Journal of Clinical Endocrinology and Metabolism* **106** e2381–e2392. (<https://doi.org/10.1210/clinem/dgab034>)
- Love MS & McNamara CW 2021 Phenotypic screening techniques for Cryptosporidium drug discovery. *Expert Opinion on Drug Discovery* **16** 59–74. (<https://doi.org/10.1080/17460441.2020.1812577>)
- Love MS, Beasley FC, Jumani RS, Wright TM, Chatterjee AK, Huston CD, Schultz PG & McNamara CW 2017 A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis. *PLoS Neglected Tropical Diseases* **11** e0005373. (<https://doi.org/10.1371/journal.pntd.0005373>)
- Mannowetz N, Miller MR & Lishko PV 2017 Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids. *PNAS* **114** 5743–5748. (<https://doi.org/10.1073/pnas.1700367114>)
- Martins da Silva SJ, Brown SG, Sutton K, King LV, Ruso H, Gray DW, Wyatt PG, Kelly MC, Barratt CLR & Hope AG 2017 Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem. *Human Reproduction* **32** 974–984. (<https://doi.org/10.1093/humrep/dex055>)
- Matamoros-Volante A, Moreno-Irusta A, Torres-Rodriguez P, Giojalas L, Gervasi MG, Visconti PE & Treviño CL 2018 Semi-automatized segmentation method using image-based flow cytometry to study sperm physiology: the case of capacitation-induced tyrosine phosphorylation. *Molecular Human Reproduction* **24** 64–73. (<https://doi.org/10.1093/molehr/gax062>)
- McBrinn RC, Fraser J, Hope AG, Gray DW, Barratt CLR, Martins da Silva SJ & Brown SG 2019 Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function. *British Journal of Pharmacology* **176** 4521–4536. (<https://doi.org/10.1111/bph.14814>)
- Moffat JG, Vincent F, Lee JA, Eder J & Prunotto M 2017 Opportunities and challenges in phenotypic drug discovery: an industry perspective. *Nature Reviews: Drug Discovery* **16** 531–543. (<https://doi.org/10.1038/nrd.2017.111>)
- Molina LCP, Gunderson S, Riley J, Lybaert P, Borrego-Alvarez A, Jungheim ES & Santi CM 2019 Membrane potential determined by flow cytometry predicts fertilizing ability of human sperm. *Frontiers in Cell and Developmental Biology* **7** 387. (<https://doi.org/10.3389/fcell.2019.00387>)
- Mortimer D & Mortimer ST 2013 Computer-aided sperm analysis (CASA) of sperm motility and hyperactivation. *Methods in Molecular Biology* **927** 77–87. (https://doi.org/10.1007/978-1-62703-038-0_8)
- Mortimer D, Curtis EF & Miller RG 1987 Specific labelling by peanut agglutinin of the outer acrosomal membrane of the human spermatozoon. *Journal of Reproduction and Fertility* **81** 127–135. (<https://doi.org/10.1530/jrf.0.0810127>)
- Moscatelli N, Spagnolo B, Pisanello M, Lemma ED, De Vittorio M, Zara V, Pisanello F & Ferramosca A 2017 Single-cell-based evaluation of sperm progressive motility via fluorescent assessment of mitochondria membrane potential. *Scientific Reports* **7** 17931. (<https://doi.org/10.1038/s41598-017-18123-1>)
- Nandagiri A, Gaikwad AS, Potter DL, Nosrati R, Soria J, O'Bryan MK, Jadhav S & Prabhakar R 2021 Flagellar energetics from high-resolution imaging of beating patterns in tethered mouse sperm. *eLife* **10** e62524. (<https://doi.org/10.7554/eLife.62524>)
- Oehninger S & Ombelet W 2019 Limits of current male fertility testing. *Fertility and Sterility* **111** 835–841. (<https://doi.org/10.1016/j.fertnstert.2019.03.005>)
- Pant N, Pant AB, Chaturvedi PK, Shukla M, Mathur N, Gupta YK & Saxena DK 2013 Semen quality of environmentally exposed human population: the toxicological consequence. *Environmental Science and Pollution Research International* **20** 8274–8281. (<https://doi.org/10.1007/s11356-013-1813-8>)

- Patterson S & Fairlamb AH 2019 Current and future prospects of nitro-compounds as drugs for trypanosomiasis and leishmaniasis. *Current Medicinal Chemistry* **26** 4454–4475. (<https://doi.org/10.2174/0929867325666180426164352>)
- Rehfeld A 2020 Revisiting the action of steroids and triterpenoids on the human sperm Ca²⁺ channel CatSper. *Molecular Human Reproduction* **26** 816–824. (<https://doi.org/10.1093/molehr/gaaa062>)
- Rehfeld A, Andersson AM & Skakkebaek NE 2020 Bisphenol A diglycidyl ether (BADGE) and bisphenol analogs, but not bisphenol A (BPA), activate the CatSper Ca(2+) channel in human sperm. *Frontiers in Endocrinology* **11** 324. (<https://doi.org/10.3389/fendo.2020.00324>)
- Reynolds-Wright JJ & Anderson R 2019 Male contraception: where are we going and where have we been? *BMJ Sexual and Reproductive Health* **45** 236–242. (<https://doi.org/10.1136/bmj.srh-2019-200395>)
- Schiffer C, Müller A, Egeberg DL, Alvarez L, Brenker C, Rehfeld A, Frederiksen H, Wäschle B, Kaupp UB, Balbach M *et al.* 2014 Direct action of endocrine disrupting chemicals on human sperm. *EMBO Reports* **15** 758–765. (<https://doi.org/10.15252/embr.201438869>)
- Schlegel PN, Sigman M, Collura B, De Jonge CJ, Eisenberg ML, Lamb DJ, Mulhall JP, Niederberger C, Sandlow JL, Sokol RZ *et al.* 2021 Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. *Fertility and Sterility* **115** 54–61. (<https://doi.org/10.1016/j.fertnstert.2020.11.015>)
- Sumner RN, Tomlinson M, Craigon J, England GCW & Lea RG 2019 Independent and combined effects of diethylhexyl phthalate and polychlorinated biphenyl 153 on sperm quality in the human and dog. *Scientific Reports* **9** 3409. (<https://doi.org/10.1038/s41598-019-39913-9>)
- Tardif S, Madamidola OA, Brown SG, Frame L, Lefievre L, Wyatt PG, Barratt CL & Martins Da Silva SJ 2014 Clinically relevant enhancement of human sperm motility using compounds with reported phosphodiesterase inhibitor activity. *Human Reproduction* **29** 2123–2135. (<https://doi.org/10.1093/humrep/deu196>)
- Thirumalai A & Amory JK 2021 Emerging approaches to male contraception. *Fertility and Sterility* **115** 1369–1376. (<https://doi.org/10.1016/j.fertnstert.2021.03.047>)
- Tomlinson MJ, Kessopoulou E & Barratt CL 1999 The diagnostic and prognostic value of traditional semen parameters. *Journal of Andrology* **20** 588–593.
- Trötschel C, Hamzeh H, Alvarez L, Pascal R, Lavryk F, Bönigk W, Körschen HG, Müller A, Poetsch A, Rennhack A *et al.* 2020 Absolute proteomic quantification reveals design principles of sperm flagellar chemosensation. *EMBO Journal* **39** e102723. (<https://doi.org/10.15252/embj.2019102723>)
- Williams HL, Mansell S, Alasmari W, Brown SG, Wilson SM, Sutton KA, Miller MR, Lishko PV, Barratt CL, Publicover SJ *et al.* 2015 Specific loss of CatSper function is sufficient to compromise fertilizing capacity of human spermatozoa. *Human Reproduction* **30** 2737–2746. (<https://doi.org/10.1093/humrep/dev243>)
- Woodland A, Thompson S, Cleghorn LA, Norcross N, De Rycker M, Grimaldi R, Hallyburton I, Rao B, Norval S, Stojanovski L *et al.* 2015 Discovery of inhibitors of Trypanosoma brucei by phenotypic screening of a focused protein kinase library. *ChemMedChem* **10** 1809–1820. (<https://doi.org/10.1002/cmdc.201500300>)
- World Health Organization Task Force on Methods for the Regulation of Male Fertility 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. *Fertility and Sterility* **65** 821–829. ([https://doi.org/10.1016/S0015-0282\(16\)58221-1](https://doi.org/10.1016/S0015-0282(16)58221-1))
- Yuan Y, Ding X, Cheng Y, Kang H, Luo T, Zhang X, Kuang H, Chen Y, Zeng X & Zhang D 2020 PFOA evokes extracellular Ca(2+) influx and compromises progesterone-induced response in human sperm. *Chemosphere* **241** 125074. (<https://doi.org/10.1016/j.chemosphere.2019.125074>)
- Zhao R, Dai H, Arias RJ, De Blas GA, Orta G, Pavarotti MA, Shen R, Perozo E, Mayorga LS, Darszon A *et al.* 2021 Direct activation of the proton channel by albumin leads to human sperm capacitation and sustained release of inflammatory mediators by neutrophils. *Nature Communications* **12** 3855. (<https://doi.org/10.1038/s41467-021-24145-1>)
- Ziegler S, Sievers S & Waldmann H 2021 Morphological profiling of small molecules. *Cell Chemical Biology* **28** 300–319. (<https://doi.org/10.1016/j.chembiol.2021.02.012>)

Received 17 September 2021

First decision 26 October 2021

Revised manuscript received 1 December 2021

Accepted 9 December 2021